Pediatrix Medical Group (NYSE:MD) CEO Mark Ordan Sells 23,000 Shares

Pediatrix Medical Group, Inc. (NYSE:MD) CEO Mark Ordan sold 23,000 shares of the stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $22.41, for a total value of $515,430.00. Following the sale, the chief executive officer directly owned 302,805 shares of the company’s stock, valued at approximately $6,785,860.05. This trade represents a 7.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Pediatrix Medical Group Trading Down 3.1%

Shares of NYSE MD traded down $0.70 during mid-day trading on Thursday, hitting $21.87. The stock had a trading volume of 42,312 shares, compared to its average volume of 803,766. The business has a 50 day moving average price of $20.73 and a two-hundred day moving average price of $16.92. Pediatrix Medical Group, Inc. has a 1 year low of $11.84 and a 1 year high of $24.99. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 1.83. The firm has a market cap of $1.88 billion, a P/E ratio of 11.48 and a beta of 0.77.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings results on Monday, November 3rd. The company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.21. The business had revenue of $492.88 million for the quarter, compared to analyst estimates of $476.45 million. Pediatrix Medical Group had a net margin of 8.44% and a return on equity of 20.45%. The company’s revenue was down 3.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.44 EPS. On average, equities analysts anticipate that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on MD shares. UBS Group lifted their price objective on Pediatrix Medical Group from $16.50 to $23.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 5th. Truist Financial lifted their target price on shares of Pediatrix Medical Group from $17.00 to $24.00 and gave the company a “hold” rating in a report on Monday, November 10th. Zacks Research upgraded shares of Pediatrix Medical Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 21st. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Pediatrix Medical Group in a research report on Monday. Finally, Leerink Partners upped their target price on shares of Pediatrix Medical Group from $14.50 to $17.00 and gave the company a “market perform” rating in a research note on Friday, September 5th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Institutional Investors Weigh In On Pediatrix Medical Group

A number of large investors have recently made changes to their positions in MD. Victory Capital Management Inc. grew its position in shares of Pediatrix Medical Group by 30.7% during the 3rd quarter. Victory Capital Management Inc. now owns 4,126,207 shares of the company’s stock valued at $69,114,000 after acquiring an additional 968,553 shares during the period. American Century Companies Inc. grew its holdings in Pediatrix Medical Group by 38.9% during the third quarter. American Century Companies Inc. now owns 2,682,976 shares of the company’s stock valued at $44,940,000 after purchasing an additional 751,109 shares during the period. Nuveen LLC purchased a new stake in Pediatrix Medical Group in the first quarter worth about $8,024,000. Ameriprise Financial Inc. raised its stake in shares of Pediatrix Medical Group by 175.4% in the second quarter. Ameriprise Financial Inc. now owns 744,473 shares of the company’s stock worth $10,683,000 after buying an additional 474,186 shares during the period. Finally, BNP Paribas Financial Markets lifted its position in shares of Pediatrix Medical Group by 669.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 476,098 shares of the company’s stock valued at $6,832,000 after buying an additional 414,216 shares in the last quarter. 97.71% of the stock is currently owned by institutional investors.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.